Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Single‐agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study

Published:2019-12-02 Issue:5 Volume:190 Page:
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cejalvo María J.¹,Legarda Mario¹^ORCID,Abella Eugenia²,Cabezudo Elena³,Encinas Cristina⁴,García‐Feria Ana⁵,Gironella Mercedes⁶,Iñigo Belén⁷,Martín Jesús⁸,Ribas Paz¹,Ruíz Mª Ángeles⁹,González Yolanda¹⁰,Vicuña Isabel¹¹,Ramírez Ángel¹²,Fernández Pascual¹³,Rubia Javier¹¹⁴^ORCID

Affiliation:

1. Department of Hematology University Hospital Doctor Peset Valencia Spain

2. Department of Hematology Hospital del Mar Barcelona Spain

3. Department of Hematology Hospital Sant Joan de Déu Barcelona Spain

4. Department of Hematology Hospital Gregorio Marañón Madrid Spain

5. Department of Hematology Hospital de Manises Valencia Spain

6. Department of Hematology Hospital Vall d’Hebron Barcelona Spain

7. Department of Hematology Hospital Clínico San Carlos Madrid Spain

8. Department of Hematology Hospital Virgen del Rocío Sevilla Spain

9. Department of Hematology Hospital Francesc Borja Gandía Spain

10. Department of Hematology Instituto Catalán de Oncología Girona Spain

11. Department of Hematology Hospital La Princesa Madrid Spain

12. Department of Hematology Hospital Central de Asturias Oviedo Spain

13. Department of Hematology Hospital General Alicante Spain

14. Internal Medicine School of Medicine and Dentistry Catholic University of Valencia Valencia Spain

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16286

Reference15 articles.

1. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study

2. Treatment of kidney failure in multiple myeloma by chronic hemodialysis. Apropos of 4 cases;Chavaz A.;La Nouvelle Presse Medicale,1976

3. Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group

4. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial

5. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease;Pharmaceuticals;2024-08-05

2. Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients;Life;2024-03-15

3. Use of daratumumab in therapy of patients with newly diagnosed multiple myeloma complicated by dialysis-dependent kidney failure: literature review and clinical observation;MD-Onco;2023-09-20

4. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07

5. Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study;American Journal of Hematology;2023-06-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3